Parker J O, Enjalbert M, Bernstein V
Department of Medicine, Queen's University, Kingston, Ontario, Canada.
Cardiovasc Drugs Ther. 1988 Mar;1(6):661-4. doi: 10.1007/BF02125752.
Thirty-six patients with chronic, stable angina pectoris were studied during 2-week treatment periods in which they received, in a randomized double-blind, crossover study, a new calcium entry blocking agent, isradipine, 7.5 mg three times daily or placebo. Antianginal efficacy was determined by treadmill exercise testing carried out 3 and 9 hours after drug administration on the final day of each treatment period. During placebo therapy, treadmill exercise time to the onset of angina (P1) and to the development of moderate angina (P2) was similar at 3 and 9 hours and similar to the placebo run-in period. During isradipine therapy, treadmill exercise time 3 hours after dosing was greater than with placebo therapy (P1 312 +/- 23.0 vs. 267 +/- 19.5 seconds, p less than 0.001; P2 410 +/- 20.2 vs. 355 +/- 18.8 seconds, p less than 0.002). Nine hours after drug administration, the results of exercise testing were similar to placebo.
在为期2周的治疗期间，对36例慢性稳定型心绞痛患者进行了研究。在随机双盲交叉研究中，他们接受了一种新型钙通道阻滞剂伊拉地平，每日3次，每次7.5毫克，或安慰剂。抗心绞痛疗效通过在每个治疗期最后一天给药后3小时和9小时进行的平板运动试验来确定。在安慰剂治疗期间，在3小时和9小时时，达到心绞痛发作（P1）和中度心绞痛发作（P2）的平板运动时间与安慰剂导入期相似。在伊拉地平治疗期间，给药后3小时的平板运动时间比安慰剂治疗时长（P1 312±23.0秒对267±19.5秒，p<0.001；P2 410±20.2秒对355±18.8秒，p<0.002）。给药9小时后，运动试验结果与安慰剂相似。
